Genomic Testing and Biomarker-Driven Treatment Selection in Advanced Prostate CancerGenomic and biomarker testing in advanced prostate cancer has shifted from a niche subspecialty consideration to a...3 min read
Hear+Now: When Patient Awareness Outpaces the mCRPC Treatment ConversationModern oncologists face a growing clinical paradox: metastatic castration-resistant prostate cancer (mCRPC) patients frequently arrive hyper-aware of cutting-edge therapies, yet they remain...3 min read
Recognizing Patient Readiness for the Next-Line Conversation in Metastatic Castration-Resistant Prostate CancerClinical assessments of when a patient is "ready" to discuss next-line treatment in metastatic castration-resistant prostate cancer (mCRPC) often arrive a step behind the patient...3 min read
Sequencing Systemic Therapy After Novel Hormonal Therapy in Metastatic Castration-Resistant Prostate CancerThe decision point after progression on a first novel hormonal therapy (NHT) in metastatic castration-resistant prostate cancer (mCRPC) carries several class-level options, each with...4 min read
Bone Health Management in Advanced Prostate Cancer on Long-Term Androgen Deprivation TherapyLong-term androgen deprivation therapy (ADT) is foundational across the advanced prostate cancer treatment landscape. Its bone health consequences are...3 min read
Test Your mCRPC Treatment Decision KnowledgeTreatment decisions in metastatic castration-resistant prostate cancer (mCRPC) have grown more nuanced as biomarker testing, imaging, and the post-novel-hormonal-therapy (NHT) and post-docetaxel...1 min read
The Symptom Burden mCRPC Patients Carry Before ChemotherapyThe tolerability conversation in metastatic castration-resistant prostate cancer (mCRPC) often rests on...3 min read
Reframing Taxane Tolerability in Advanced Prostate CancerMisperceptions of taxane chemotherapy tolerability in advanced prostate cancer often rest on an...3 min read
